YTX-9184

YTX-9184 is an investigational **small molecule** inhibitor of **stearoyl-CoA desaturase** being developed by **Yumanity Therapeutics** as an orally available, brain-penetrant therapy for **dementia with Lewy bodies**. The program was described as a follow-on to YTX-7739, applying stearoyl-CoA desaturase inhibition to modulate lipid biology linked to **alpha-synuclein** misfolding and aggregation in synucleinopathies. Publicly available context indicates IND-enabling safety pharmacology and toxicology work began in 2020 with an anticipated Phase 1 start in 2021, and preclinical reports have also described activity in glioblastoma models, although the core neurodegeneration positioning has been dementia with Lewy bodies.